Company: MIRM
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001759425-25-000054
Chunk: 343

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 343
---
 thousands)

 Three Months Ended September 30,Nine Months Ended September 30, 2025202420252024Net income (loss)$2,905 $(14,235)$(17,633)$(64,152)Other comprehensive income (loss):Unrealized gain on available-for-sale investments68 291 33 298 Cumulative translation adjustments(383)1,106 377 (1,022)Comprehensive income (loss)$2,590 $(12,838)$(17,223)$(64,876)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands, except share amounts)

 Common StockAdditionalPaid-InCapitalAccumulatedDeficitAccumulatedOtherComprehensive Income (Loss) TotalStockholders’Equity  SharesAmountBalance as of December 31, 2024 48,338,096$5 $870,189 $(644,181)$(373)$225,640 Issuance of common stock in connection with equity award plans1,112,939— 6,359 — — 6,359 Conversion of convertible notes, net188— 6 — — 6 Stock-based compensation—— 15,813 — — 15,813 Net loss—— — (14,677)— (14,677)Other comprehensive income—— — — 115 115 Balance as of March 31, 202549,451,2235 892,367 (658,858)(258)233,256 Issuance of common stock in connection with equity award plans547,323— 6,575 — — 6,575 Issuance of common stock in connection with employee stock purchase plan59,752— 2,113 — — 2,113 Conversion of convertible notes, net94— 3 — — 3 Stock-based compensation—— 18,462 — — 18,462 Net loss—— — (5,861)— (5,861)Other comprehensive income—— — — 610 610 Balance as of June 30, 202550,058,3925 919,520 (664,719)352 255,158 Issu